Bradley K. Ackerson

6.1k total citations · 3 hit papers
100 papers, 3.4k citations indexed

About

Bradley K. Ackerson is a scholar working on Epidemiology, Infectious Diseases and Health. According to data from OpenAlex, Bradley K. Ackerson has authored 100 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Epidemiology, 42 papers in Infectious Diseases and 29 papers in Health. Recurrent topics in Bradley K. Ackerson's work include SARS-CoV-2 and COVID-19 Research (34 papers), Vaccine Coverage and Hesitancy (29 papers) and COVID-19 Clinical Research Studies (21 papers). Bradley K. Ackerson is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (34 papers), Vaccine Coverage and Hesitancy (29 papers) and COVID-19 Clinical Research Studies (21 papers). Bradley K. Ackerson collaborates with scholars based in United States, Italy and Belgium. Bradley K. Ackerson's co-authors include Jeff Slezak, Lina S. Sy, Sara Y. Tartof, Vennis Hong, Hung Fu Tseng, Yi Luo, John M. McLaughlin, Luis Jódar, Lei Qian and Heidi Fischer and has published in prestigious journals such as The Lancet, JAMA and Nature Medicine.

In The Last Decade

Bradley K. Ackerson

93 papers receiving 3.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

2021 727 citations Sara Y. Tartof, Jeff Slezak et al. profile →
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

2022 315 citations Hung Fu Tseng, Bradley K. Ackerson et al. Nature Medicine profile →
Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system

2023 74 citations Joseph A. Lewnard, John M. McLaughlin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bradley K. Ackerson United States	26	2.1k	1.1k	929	396	300	100	3.4k
John M. McLaughlin United States	29	2.3k 1.1×	1.1k 1.0×	1.3k 1.3×	726 1.8×	220 0.7×	105	4.3k
Manish Pareek United Kingdom	32	1.9k 0.9×	1.6k 1.5×	568 0.6×	353 0.9×	261 0.9×	152	4.0k
Jim McMenamin United Kingdom	34	1.6k 0.7×	2.3k 2.1×	755 0.8×	639 1.6×	208 0.7×	109	4.0k
Ruth Simmons United Kingdom	18	2.5k 1.2×	480 0.4×	944 1.0×	749 1.9×	335 1.1×	69	3.4k
Mark A. Katz United States	22	1.7k 0.8×	967 0.9×	840 0.9×	553 1.4×	109 0.4×	75	3.1k
Sara E. Oliver United States	20	1.6k 0.7×	677 0.6×	1.0k 1.1×	384 1.0×	133 0.4×	54	2.9k
Tom T. Shimabukuro United States	37	2.5k 1.2×	1.2k 1.1×	1.6k 1.7×	209 0.5×	342 1.1×	92	4.8k
Gavin Dabrera United Kingdom	17	2.2k 1.1×	576 0.5×	857 0.9×	741 1.9×	227 0.8×	61	3.2k
Elise Tessier United Kingdom	15	2.4k 1.1×	503 0.4×	1.2k 1.3×	829 2.1×	222 0.7×	32	3.3k
Tyra Grove Krause Denmark	28	847 0.4×	1.1k 1.0×	648 0.7×	297 0.8×	144 0.5×	100	2.5k

Countries citing papers authored by Bradley K. Ackerson

Since Specialization

Citations

This map shows the geographic impact of Bradley K. Ackerson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bradley K. Ackerson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bradley K. Ackerson more than expected).

Fields of papers citing papers by Bradley K. Ackerson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bradley K. Ackerson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bradley K. Ackerson. The network helps show where Bradley K. Ackerson may publish in the future.

Co-authorship network of co-authors of Bradley K. Ackerson

This figure shows the co-authorship network connecting the top 25 collaborators of Bradley K. Ackerson. A scholar is included among the top collaborators of Bradley K. Ackerson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bradley K. Ackerson. Bradley K. Ackerson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Skarbinski, Jacek, Katia Bruxvoort, Heidi Fischer, et al.. (2025). Risk of Incident Tuberculosis Disease in a Large Integrated Health Care System in California, 2004–2022. Open Forum Infectious Diseases. 12(3). ofaf103–ofaf103. 1 indexed citations

Patrick, Rudy, Parag Mahale, Bradley K. Ackerson, et al.. (2025). Respiratory syncytial virus vaccine uptake among adults aged ≥60 years in a large, integrated healthcare system in Southern California 2023–2024. Vaccine. 53. 127033–127033. 2 indexed citations

Rayens, Emily, Lina S. Sy, Lei Qian, et al.. (2025). Effectiveness and safety of the recombinant zoster vaccine in individuals ≥50 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study. Annals of the Rheumatic Diseases. 84(6). 960–969. 1 indexed citations

Rayens, Emily, Lina S. Sy, Lei Qian, et al.. (2025). Adjuvanted Recombinant Zoster Vaccine is Effective Against Herpes Zoster Ophthalmicus, and is Associated With Lower Risk of Acute Myocardial Infarction and Stroke in Adults Aged ≥50 Years. Clinical Infectious Diseases. 81(5). e441–e445.

Tartof, Sara Y., Jeff Slezak, Laura Puzniak, et al.. (2024). Effectiveness of BNT162b2 XBB Vaccine Against XBB and JN.1 Sublineages. Open Forum Infectious Diseases. 11(7). ofae370–ofae370. 7 indexed citations

Rayens, Emily, Jennifer H Ku, Lina S. Sy, et al.. (2024). Comparative Effectiveness of Cell‐Based Versus Egg‐Based Influenza Vaccines in Prevention of Influenza Hospitalization During the 2022–2023 Season Among Adults 18–64 Years. Influenza and Other Respiratory Viruses. 18(12). e70025–e70025. 2 indexed citations

Lewnard, Joseph A., Parag Mahale, Deborah E. Malden, et al.. (2024). Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage. Nature Communications. 15(1). 8550–8550. 8 indexed citations

Lewnard, Joseph A., Vennis Hong, Lindsay R. Grant, et al.. (2024). Association of Pneumococcal Conjugate Vaccination With Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Older Adult Recipients of Coronavirus Disease 2019 Vaccines: A Longitudinal Cohort Study. The Journal of Infectious Diseases. 230(5). e1082–e1091.

Tseng, Hung Fu, Bradley K. Ackerson, Katia Bruxvoort, et al.. (2023). Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nature Communications. 14(1). 189–189. 47 indexed citations

10.

Ku, Jennifer H, Lina S. Sy, Lei Qian, et al.. (2023). Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study. Vaccine. 41(29). 4212–4219. 4 indexed citations

11.

Skarbinski, Jacek, Heidi Fischer, Vennis Hong, et al.. (2023). Real‐World Evidence to Supplement Randomized Clinical Trials: Tocilizumab for Severe COVID‐19 Pneumonia vs. a Cohort Receiving Standard of Care. Clinical Pharmacology & Therapeutics. 114(5). 1073–1081. 3 indexed citations

12.

Huang, Chen‐Yang, Jim Leng, Bradley K. Ackerson, et al.. (2023). Evaluating the Reliability of Chat-GPT Model Responses for Radiation Oncology Patient Inquiries. International Journal of Radiation Oncology*Biology*Physics. 117(2). e383–e383. 9 indexed citations

13.

Malden, Deborah E., Sara Y. Tartof, Bradley K. Ackerson, et al.. (2022). Natural Language Processing for Improved Characterization of COVID-19 Symptoms: Observational Study of 350,000 Patients in a Large Integrated Health Care System. JMIR Public Health and Surveillance. 8(12). e41529–e41529. 17 indexed citations

14.

Tseng, Hung Fu, Bradley K. Ackerson, Yi Luo, et al.. (2022). Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nature Medicine. 28(5). 1063–1071. 315 indexed citations breakdown →

15.

Skarbinski, Jacek, Liyan Liu, Vennis Hong, et al.. (2022). Retrospective cohort study to assess the association between treatment with tocilizumab and mortality among mechanically ventilated patients with COVID-19. BMJ Open. 12(10). e060358–e060358. 1 indexed citations

16.

Bruxvoort, Katia, Bradley K. Ackerson, Lina S. Sy, et al.. (2021). Recombinant Adjuvanted Zoster Vaccine and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults. The Journal of Infectious Diseases. 225(11). 1915–1922. 30 indexed citations

17.

Ackerson, Bradley K., Lei Qian, Lina S. Sy, et al.. (2021). Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older. Vaccine. 39(6). 926–932. 17 indexed citations

18.

Becerra-Culqui, Tracy A., Lina S. Sy, Bradley K. Ackerson, et al.. (2019). Safety of quadrivalent meningococcal conjugate vaccine in infants and toddlers 2 to 23-months old. Vaccine. 38(2). 228–234. 4 indexed citations

19.

Jacobsen, Steven J., Lina S. Sy, Bradley K. Ackerson, et al.. (2012). An unmasking phenomenon in an observational post-licensure safety study of adolescent girls and young women. Vaccine. 30(31). 4585–4587. 15 indexed citations

20.

Krogstad, Paul, Yongzhi Geng, Osvaldo Rey, et al.. (2002). Human Immunodeficiency Virus Nucleocapsid Protein Polymorphisms Modulate the Infectivity of RNA Packaging Mutants. Virology. 294(2). 282–288. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact